EdgarLookup

LOGITECH INTERNATIONAL S.A. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that LOGITECH INTERNATIONAL S.A. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
13.9%
Profit Margin
Net income ÷ revenue
17.8%
Return on Assets
Net income ÷ assets
0.66x
Debt-to-Equity
Total liabilities ÷ equity
+6%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $4.55B May 23, 2025
FY2025 Mar 31, 2024 $4.30B May 23, 2025
FY2025 Mar 31, 2023 $4.54B May 23, 2025
FY2024 Mar 31, 2022 $5.48B May 16, 2024
FY2023 Mar 31, 2021 $5.25B May 17, 2023
FY2022 Mar 31, 2020 $2.98B May 18, 2022
FY2021 Mar 31, 2019 $2.79B May 12, 2021
FY2020 Mar 31, 2018 $2.57B May 27, 2020
FY2019 Mar 31, 2017 $2.22B May 17, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2018 Mar 31, 2018 $2.57B May 21, 2018
FY2018 Mar 31, 2017 $2.22B May 21, 2018
FY2018 Mar 31, 2016 $2.02B May 21, 2018
FY2017 Mar 31, 2015 $2.00B May 26, 2017
FY2016 Mar 31, 2014 $2.01B May 23, 2016
FY2015 Mar 31, 2013 $2.10B Jun 5, 2015
FY2014 Mar 31, 2012 $2.32B Nov 13, 2014
FY2012 Mar 31, 2011 $2.37B Aug 7, 2013
FY2011 Mar 31, 2010 $1.97B May 30, 2012
FY2010 Mar 31, 2009 $2.21B May 27, 2011

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $1.96B May 23, 2025
FY2025 Mar 31, 2024 $1.78B May 23, 2025
FY2025 Mar 31, 2023 $1.72B May 23, 2025
FY2024 Mar 31, 2022 $2.26B May 16, 2024
FY2023 Mar 31, 2021 $2.34B May 17, 2023
FY2022 Mar 31, 2020 $1.12B May 18, 2022
FY2021 Mar 31, 2019 $1.04B May 12, 2021
FY2020 Mar 31, 2018 $909.24M May 27, 2020
FY2019 Mar 31, 2017 $820.04M May 17, 2019
FY2018 Mar 31, 2016 $681.05M May 21, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $631.53M May 23, 2025
FY2025 Mar 31, 2024 $612.14M May 23, 2025
FY2025 Mar 31, 2023 $364.58M May 23, 2025
FY2024 Mar 31, 2022 $644.51M May 16, 2024
FY2023 Mar 31, 2021 $947.26M May 17, 2023
FY2010 Mar 31, 2011 $128.46M May 27, 2011
FY2010 Mar 31, 2010 $64.96M May 27, 2011
FY2010 Mar 31, 2009 $107.03M May 27, 2011

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $654.86M May 23, 2025
FY2025 Mar 31, 2024 $587.34M May 23, 2025
FY2025 Mar 31, 2023 $458.47M May 23, 2025
FY2024 Mar 31, 2022 $774.01M May 16, 2024
FY2023 Mar 31, 2021 $1.15B May 17, 2023
FY2022 Mar 31, 2020 $276.50M May 18, 2022
FY2021 Mar 31, 2019 $263.19M May 12, 2021
FY2020 Mar 31, 2018 $229.73M May 27, 2020
FY2019 Mar 31, 2017 $211.86M May 17, 2019
FY2018 Mar 31, 2016 $129.06M May 21, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $309.01M May 23, 2025
FY2025 Mar 31, 2024 $287.24M May 23, 2025
FY2025 Mar 31, 2023 $280.80M May 23, 2025
FY2024 Mar 31, 2022 $291.84M May 16, 2024
FY2023 Mar 31, 2021 $226.02M May 17, 2023
FY2022 Mar 31, 2020 $177.59M May 18, 2022
FY2021 Mar 31, 2019 $161.23M May 12, 2021
FY2020 Mar 31, 2018 $143.76M May 27, 2020
FY2019 Mar 31, 2017 $130.53M May 17, 2019
FY2018 Mar 31, 2016 $113.18M May 21, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $842.56M May 23, 2025
FY2025 Mar 31, 2024 $1.15B May 23, 2025
FY2025 Mar 31, 2023 $534.01M May 23, 2025
FY2024 Mar 31, 2022 $298.32M May 16, 2024
FY2023 Mar 31, 2021 $1.46B May 17, 2023
FY2022 Mar 31, 2020 $425.00M May 18, 2022
FY2021 Mar 31, 2019 $305.18M May 12, 2021
FY2020 Mar 31, 2018 $346.26M May 27, 2020
FY2019 Mar 31, 2017 $288.39M May 17, 2019
FY2018 Mar 31, 2016 $185.20M May 21, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $56.13M May 23, 2025
FY2025 Mar 31, 2024 $55.90M May 23, 2025
FY2025 Mar 31, 2023 $92.35M May 23, 2025
FY2024 Mar 31, 2022 $89.15M May 16, 2024
FY2023 Mar 31, 2021 $76.19M May 17, 2023
FY2022 Mar 31, 2020 $39.48M May 18, 2022
FY2021 Mar 31, 2019 $35.93M May 12, 2021
FY2020 Mar 31, 2018 $39.75M May 27, 2020
FY2019 Mar 31, 2017 $31.80M May 17, 2019
FY2018 Mar 31, 2016 $56.62M May 21, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $3.54B May 23, 2025
FY2025 Mar 31, 2024 $3.60B May 23, 2025
FY2024 Mar 31, 2023 $3.56B May 16, 2024
FY2023 Mar 31, 2022 $4.04B May 17, 2023
FY2022 Mar 31, 2021 $4.14B May 18, 2022
FY2021 Mar 31, 2020 $2.36B May 12, 2021
FY2020 Mar 31, 2019 $2.02B May 27, 2020
FY2019 Mar 31, 2018 $1.74B May 17, 2019
FY2018 Mar 31, 2017 $1.50B May 21, 2018
FY2017 Mar 31, 2016 $1.32B May 26, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $1.41B May 23, 2025
FY2025 Mar 31, 2024 $1.37B May 23, 2025
FY2024 Mar 31, 2023 $1.30B May 16, 2024
FY2023 Mar 31, 2022 $1.64B May 17, 2023
FY2022 Mar 31, 2021 $1.88B May 18, 2022
FY2021 Mar 31, 2020 $874.21M May 12, 2021
FY2020 Mar 31, 2019 $847.79M May 27, 2020
FY2019 Mar 31, 2018 $692.60M May 17, 2019
FY2018 Mar 31, 2017 $642.57M May 21, 2018
FY2017 Mar 31, 2016 $564.20M May 26, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $2.13B May 23, 2025
FY2025 Mar 31, 2024 $2.23B May 23, 2025
FY2025 Mar 31, 2023 $2.26B May 23, 2025
FY2025 Mar 31, 2022 $2.40B May 23, 2025
FY2024 Mar 31, 2021 $2.26B May 16, 2024
FY2023 Mar 31, 2020 $1.49B May 17, 2023
FY2022 Mar 31, 2019 $1.18B May 18, 2022
FY2021 Mar 31, 2018 $1.05B May 12, 2021
FY2020 Mar 31, 2017 $856.11M May 27, 2020
FY2019 Mar 31, 2016 $759.95M May 17, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $463.23M May 23, 2025
FY2025 Mar 31, 2024 $461.98M May 23, 2025
FY2025 Mar 31, 2023 $454.61M May 23, 2025
FY2024 Mar 31, 2022 $448.18M May 16, 2024
FY2023 Mar 31, 2021 $429.60M May 17, 2023
FY2022 Mar 31, 2020 $400.92M May 18, 2022
FY2021 Mar 31, 2019 $343.68M May 12, 2021
FY2020 Mar 31, 2018 $275.45M May 27, 2020
FY2019 Mar 31, 2017 $249.74M May 17, 2019
FY2018 Mar 31, 2016 $218.22M May 21, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $3.63B May 23, 2025
FY2025 Mar 31, 2024 $3.60B May 23, 2025
FY2024 Mar 31, 2023 $3.18B May 16, 2024
FY2023 Mar 31, 2022 $2.98B May 17, 2023
FY2022 Mar 31, 2021 $2.49B May 18, 2022
FY2021 Mar 31, 2020 $1.69B May 12, 2021
FY2020 Mar 31, 2019 $1.37B May 27, 2020
FY2020 Apr 1, 2018 $1.22B May 27, 2020
FY2019 Mar 31, 2018 $1.23B May 17, 2019
FY2018 Mar 31, 2017 $1.07B May 21, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $1.50B May 23, 2025
FY2025 Mar 31, 2024 $1.52B May 23, 2025
FY2024 Mar 31, 2023 $1.15B May 16, 2024
FY2023 Mar 31, 2022 $1.33B May 17, 2023
FY2022 Mar 31, 2021 $1.75B May 18, 2022
FY2021 Mar 31, 2020 $715.57M May 12, 2021
FY2020 Mar 31, 2019 $604.52M May 27, 2020
FY2019 Mar 31, 2018 $641.95M May 17, 2019
FY2018 Mar 31, 2017 $547.53M May 21, 2018
FY2018 Mar 31, 2016 $519.20M May 21, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 4 May 23, 2025
FY2025 Mar 31, 2024 3 May 23, 2025
FY2025 Mar 31, 2023 2 May 23, 2025
FY2024 Mar 31, 2022 3 May 16, 2024
FY2023 Mar 31, 2021 5 May 17, 2023
FY2022 Mar 31, 2020 2 May 18, 2022
FY2021 Mar 31, 2019 1 May 12, 2021
FY2020 Mar 31, 2018 1 May 27, 2020
FY2019 Mar 31, 2017 1 May 17, 2019
FY2018 Mar 31, 2016 0 May 21, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 4 May 23, 2025
FY2025 Mar 31, 2024 3 May 23, 2025
FY2025 Mar 31, 2023 2 May 23, 2025
FY2024 Mar 31, 2022 3 May 16, 2024
FY2023 Mar 31, 2021 5 May 17, 2023
FY2022 Mar 31, 2020 2 May 18, 2022
FY2021 Mar 31, 2019 1 May 12, 2021
FY2020 Mar 31, 2018 1 May 27, 2020
FY2019 Mar 31, 2017 1 May 17, 2019
FY2018 Mar 31, 2016 0 May 21, 2018

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2014 Mar 31, 2014 173.11M Nov 13, 2014
FY2014 Mar 31, 2013 173.11M Nov 13, 2014
FY2014 Sep 30, 2012 191.60M Nov 13, 2014
FY2012 Mar 31, 2012 191.60M Aug 7, 2013